Target intelligence / Profile preview

Liver yang hyperactivity state

Molecular classification
Other
01

Overview

Liver yang hyperactivity state describes a syndrome in Traditional Chinese Medicine characterized by symptoms such as headache, dizziness, tinnitus, facial flushing, irritability, dry mouth, and elevated blood pressure. This conceptual state is understood as a dysfunction in "liver yang" regulation, often co-occurring with "liver yin insufficiency," and is regarded as a pathogenesis for essential hypertension and sometimes associated with behavioral and neurological symptoms. Modern TCM translational studies note altered biochemical markers, autonomic imbalance, neurovascular changes, and gut microbiota composition in animal models, but it is not a molecule, receptor, or structurally defined biological entity[1][2][3][4][5][6][7]. Therapeutic approaches focus on syndrome management (symptom relief, blood pressure control) using Chinese herbal compounds, acupuncture, lifestyle modification, and integrative medicine strategies[2][5][7]. There is no canonical molecular classification, and the syndrome should not be treated as a drug target in the conventional sense.

Other names
Liver yang ascendant hyperactivityLiver-Yang hyperactivity syndromeHLYHAscendant hyperactivity of liver yang
02

Mechanism of action

Multi-mechanistic symptomatic alleviation and blood pressure reduction via diverse pathways, including modulation of renin-angiotensin system, gut microbiota, neurotransmitter metabolism (e.g., GABA/glutamate), and other TCM conceptual imbalances[3][5]

03

Biological functions

Other
04

Disease associations

HypertensionCardiovascular diseasedescribed as relating to irritability, headache, dizziness, and vascular/autonomic imbalance
05

Safety considerations

Therapeutic challenges linked to unclear molecular basisreliance on syndromic diagnosisintegration issues with Western medicine standards
06

Interacting drugs

Chinese herbal drugs (e.g., "Pingyang Jiangya Fang", "Tianma Gouteng Yin Decoction")

1 more in the full profile.

07

Biomarkers

Metabolic markers and profiles, e.g., changes in 27 potential biomarkers and 14 metabolic pathways identified in rat models (research context only, not clinically established)

Beyond the preview

Go deeper on Liver yang hyperactivity state.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Liver yang hyperactivity state.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call